Navigation Links
Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
Date:5/1/2008

SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire/ -- Proteolix, Inc. today announced that patient dosing has commenced in a Phase 2 clinical trial of carfilzomib (PR-171), a selective blocker of proteasome activity, in relapsed solid tumors. A Phase 1b dose-escalation trial of carfilzomib in patients with advanced solid tumors has recently been completed.

The Phase 2 trial will evaluate the safety and efficacy of single-agent carfilzomib in patients with recurrent or advanced solid tumors. Subjects will be enrolled and stratified according to disease type, including non-small cell lung cancer, small cell lung cancer, ovarian cancer and renal cancer. The open-label, multi-center clinical trial is a two-stage design, with pre-determined criteria for continuation after an initial cohort of patients have been treated. Patients enrolled in the study will receive carfilzomib twice a week for three weeks with a one week rest period.

"We are pleased to advance carfilzomib into Phase 2 in patients with solid tumors, building on the positive safety data and encouraging signals of activity observed in our Phase 1b trial," said Lori Kunkel, M.D., Proteolix' Chief Medical Officer. "In addition to its demonstrated anti-tumor activity against hematologic malignancies, carfilzomib's unique profile points to its potential as a new treatment for solid tumor cancers. Carfilzomib exhibits a highly selective mechanism of action for the proteasome, an important therapeutic target for cancer, and we believe this selectivity may reduce or eliminate toxicities seen with other proteasome inhibitors."

"Targeted agents with novel mechanisms of action can complement current treatment regimens and improve outcomes. Carfilzomib has demonstrated tolerability and anti-tumor activity in early studies and these Phase 2 trials in patients with solid tumors are an exciting step forward in the clinical development of the drug," said Kyri Papadopoulos, M.D., a principal investig
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. Prolexys Pharmaceuticals Initiates Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, Inc., ... over-the-counter (OTC) medicinal and healthcare products, announced it received ... H, a hemp-based, advanced headache relief product, for planned ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... 8, 2011 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... year 2010 financial results before the NASDAQ Global Select Market ... Lief, Arena,s President and Chief Executive Officer, will host a ... Time) to discuss the financial results for the fourth quarter ...
... Sciences: OTC Bulletin Board: RBCL ) -- RBC ... care and pain management products, today reported a 13% increase ... ended December 31, 2010, compared to net sales of $24.9 ... Company reported net earnings of $558,000, or $0.02 per diluted ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11 3RBC Life Sciences Reports Sales and Earnings Growth in 2010 2RBC Life Sciences Reports Sales and Earnings Growth in 2010 3
(Date:12/26/2014)... Aliso Viejo, California (PRWEB) December 26, 2014 ... have announced the TransPack Volume 5 Plugin for Final Cut ... to manipulate a hard light tool to pull off an ... Studios. “When users get their hands on TransPack Volume 5, ... TransPack Volume 5 is a set of over 50 Final ...
(Date:12/26/2014)... (DaWei Induction Heating Co.) is a comprehensive high-tech business ... of a series of induction heating equipment. Today, the ... induction brazing equipments . , According to a ... refers to the joining of two or more components ... says that there are fundamental differences in the two ...
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... a brain cancer death sentence. It is the most lethal ... are diagnosed with GBM annually in the U.S., half ... within 3 years. The treatments include highly invasive surgeries to ... dose, both leading to a very low quality of life. ...
... conducted by the University of Michigan’s researchers has revealed that those ... unsafe are likely to put on weight. As many as 16% ... in the US are reported to be overweight, while in the ... tripled since the early 1990s. ,The researchers, led ...
... one more reason to raise a toast- a formula for ... // can pep-up your spirits and relish the ... University, and author of the formula for Marks & Spencer, ... open a champagne bottle. According to smith, P = T/4.5 ...
... difficult acrobatic stunts and are paying the price with a ... ,Cheerleaders catapult in the air, climb human ... the ground. They also make it to the emergency room. ... Pediatrics estimates that 208,800 young people aged 5 to 18 ...
... that is mainly present in pain relievers. Recently there is ... // clinicians complaining about over dosage of Acetaminophen. ... 50% of these cases are unintentional. Drugs like Tylenol, Benadryl, ... as one of the main composition in them. ...
... smokers or those who have been smoking in the past have ... tomography (CT scan) to detect // lung cancer if any, ... effective treatment and thereby improve the prognosis. ,The ... family history of the dreadful disease. For those of you ...
Cached Medicine News:Health News:Radiology advance points way to non-invasive brain cancer treatment 2Health News:Surroundings Have An Effect On Weight 2Health News:Cheerleaders run high risk of injury-US study 2Health News:Painkillers Lead To Liver Failure 2Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: